18F-FDG PET/CT in primary central nervous system lymphoma in HIV-negative patients
Authors:
- Brian P. O'NeillBOBrian P. O'Neill
- Rathan M. SubramaniamRSRathan M. Subramaniam
- Robert J. WitteRWRobert J. Witte
- Brian P. MullanBMBrian P. Mullan
- Mark A. NathanMNMark A. Nathan
- Val J. LoweVLVal J. Lowe
- Patrick J. PellerPPPatrick J. Peller
- Gregory A. WisemanGWGregory A. Wiseman
- 1 November 2007
- journal article
- research article
- Published by Wolters Kluwer Health in Nuclear Medicine Communications
- Vol. 28 (11) , 834-841
Abstract
Objective To determine the value of 18F-FDG PET/CT in the different manifestations of primary central nervous system lymphoma (PCNSL) in HIV-negative patients. Methods All PCNSL and HIV-negative patients referred for PET/CT in our institution from July 2001 to June 2006 were retrospectively studied. PET/CT examinations were reviewed by two experienced readers and evaluated for each possible anatomical site of nervous system involvement: cerebral, spinal/nerve and ocular. PET/CT results were characterized as true positive or negative and false positive or negative according to the status of the disease, which was determined after the evaluation of biopsies, laboratory, clinical and imaging examinations, and follow-up. Results Forty-two PET/CT examinations were carried out in 25 PCNSL patients. For intracerebral disease, PET/CT was true positive in 13 cases, true negative in 27 and false negative in two. For disease involving spinal cord and/or nerves, PET/CT was true positive in four cases, true negative in 37 and false negative in one. For ocular disease, PET was true positive in only one case and false negative in four. The sensitivity of PET/CT in detecting active disease in the brain was 87% (13/15), in the spine/nerves 80% (4/5), and in the eyes only 20% (1/5). Conclusion PET/CT seems to be sensitive for the detection of viable intracerebral as well as for spinal and peripheral nerve disease, but not for the detection of ocular involvement.Keywords
This publication has 17 references indexed in Scilit:
- 18-FDG-PET as a Prognostic Indicator in the Treatment of Aggressive Non-Hodgkin's Lymphoma-Comparison with CTLeukemia & Lymphoma, 2000
- Positron emission tomography with 18F-FDG to detect residual disease after therapy for malignant lymphomaNuclear Medicine Communications, 1998
- 18-F-fluorodeoxyglucose-positron emission tomography as a new approach to detect lymphomatous bone marrow.Journal of Clinical Oncology, 1998
- Lymphoma: role of whole-body 2-deoxy-2-[F-18]fluoro-D-glucose (FDG) PET in nodal staging.Radiology, 1997
- Importance of complete staging in non-Hodgkin's lymphoma presenting as a cerebral mass lesionCancer, 1996
- Clinicopathological Features, Survival And Prognostic Factors Of Primary Central Nervous System Lymphomas: Trends in Incidence of Primary Central Nervous System Lymphomas and Primary Malignant Brain Tumors in A Well-Defined Geographical Area; Population-Based Data from the Danish Lymphoma Registry, Lyfo, And the Danish Cancer ReistryLeukemia & Lymphoma, 1995
- Pathology with clinical correlations of primary central nervous system non-Hodgkin's lymphoma. The massachusetts general hospital experience 1958-1989Cancer, 1994
- Primary Central Nervous System LymphomaMayo Clinic Proceedings, 1989
- Primary central nervous system lymphomaJournal of Neurosurgery, 1988
- Primary lymphomas of the central nervous system: patterns of failure and factors that influence survival.Journal of Clinical Oncology, 1985